Review
Copyright ©The Author(s) 2021.
World J Gastroenterol. Dec 21, 2021; 27(47): 8081-8102
Published online Dec 21, 2021. doi: 10.3748/wjg.v27.i47.8081
Table 2 Main drugs under development for the treatment of hepatitis D virus (with effect from phase II)
Bulevirtide
Entry inhibitor
Germany
Approved in Europe
LonafarnibPrenylation inhibitorUnited StatesPhase III
REP 2139HBsAg inhibitorCanadaPhase II
EzetimibeNTCP inhibitorPakistanPhase II